Y Intercept Hong Kong Ltd Grows Position in Amgen Inc. $AMGN

Y Intercept Hong Kong Ltd raised its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 97.9% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 33,221 shares of the medical research company’s stock after acquiring an additional 16,434 shares during the period. Y Intercept Hong Kong Ltd’s holdings in Amgen were worth $9,375,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in AMGN. Wealth Quarterback LLC boosted its holdings in Amgen by 1.6% in the third quarter. Wealth Quarterback LLC now owns 2,210 shares of the medical research company’s stock worth $624,000 after purchasing an additional 34 shares during the last quarter. Fairvoy Private Wealth LLC lifted its holdings in shares of Amgen by 1.1% during the 2nd quarter. Fairvoy Private Wealth LLC now owns 3,171 shares of the medical research company’s stock valued at $885,000 after buying an additional 35 shares during the period. Nicholson Wealth Management Group LLC boosted its stake in shares of Amgen by 0.6% in the 2nd quarter. Nicholson Wealth Management Group LLC now owns 5,918 shares of the medical research company’s stock worth $1,652,000 after buying an additional 35 shares during the last quarter. LS Investment Advisors LLC grew its holdings in shares of Amgen by 4.1% in the third quarter. LS Investment Advisors LLC now owns 885 shares of the medical research company’s stock worth $250,000 after acquiring an additional 35 shares during the period. Finally, Crown Wealth Group LLC increased its position in Amgen by 4.0% during the third quarter. Crown Wealth Group LLC now owns 910 shares of the medical research company’s stock valued at $257,000 after acquiring an additional 35 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors.

Amgen Stock Performance

Shares of NASDAQ AMGN opened at $344.75 on Friday. The stock has a market cap of $185.64 billion, a PE ratio of 26.64, a price-to-earnings-growth ratio of 3.09 and a beta of 0.45. Amgen Inc. has a 1 year low of $261.43 and a 1 year high of $349.98. The firm has a fifty day moving average price of $332.07 and a 200-day moving average price of $307.54. The company has a debt-to-equity ratio of 5.45, a current ratio of 1.28 and a quick ratio of 0.99.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, November 4th. The medical research company reported $5.64 earnings per share for the quarter, beating analysts’ consensus estimates of $5.01 by $0.63. Amgen had a net margin of 19.47% and a return on equity of 162.59%. The company had revenue of $9.56 billion for the quarter, compared to analysts’ expectations of $8.98 billion. During the same quarter in the previous year, the company earned $5.58 EPS. Amgen’s revenue for the quarter was up 12.4% on a year-over-year basis. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. Equities analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, February 13th will be given a dividend of $2.52 per share. This is an increase from Amgen’s previous quarterly dividend of $2.38. This represents a $10.08 annualized dividend and a dividend yield of 2.9%. The ex-dividend date is Friday, February 13th. Amgen’s dividend payout ratio (DPR) is 77.90%.

Analysts Set New Price Targets

Several research analysts have issued reports on AMGN shares. Daiwa Capital Markets raised their target price on Amgen from $310.00 to $370.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 18th. HSBC reiterated a “buy” rating and issued a $425.00 price objective on shares of Amgen in a research note on Wednesday, December 10th. Morgan Stanley reduced their target price on shares of Amgen from $329.00 to $304.00 and set an “equal weight” rating for the company in a report on Friday, December 12th. Guggenheim increased their price target on shares of Amgen from $288.00 to $305.00 and gave the stock a “neutral” rating in a research report on Thursday, November 6th. Finally, The Goldman Sachs Group boosted their price objective on shares of Amgen from $400.00 to $403.00 and gave the company a “buy” rating in a research report on Thursday, January 8th. Two research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $339.24.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen announced a dividend increase to $2.52, reinforcing its income profile and making the stock more attractive to dividend-focused investors. This supports longer-term investor demand. Amgen (NASDAQ:AMGN) Has Announced That It Will Be Increasing Its Dividend To $2.52
• Positive Sentiment: Amgen expanded its obesity/GLP‑1 strategy via a collaboration with Ro, signaling potential new mid-term revenue streams if programs progress. Pipeline progress tends to boost investor sentiment for growth prospects. Amgen (AMGN) expands obesity strategy with Ro collaboration on GLP-1 therapies
• Positive Sentiment: The stock recently hit a 52-week high, reflecting recent buyer interest and validation of recent corporate moves and sentiment around the pipeline. Amgen stock hits 52-week high at $346.41
• Neutral Sentiment: Zacks notes AMGN is a trending stock on its platform, outlining investor attention and search interest but providing no new catalyst; useful context on market interest but not a direct driver. Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock
• Neutral Sentiment: Analyst commentary and deep-dive pieces (e.g., Seeking Alpha on MariTide obesity/T2D potential) highlight upside from R&D, but these are longer‑horizon, research-driven views rather than immediate catalysts. Amgen: A Buy In 2026 On Exciting MariTide Obesity – T2D Potential
• Negative Sentiment: Sagebrush has sued Amgen over disputes tied to the 340B program, introducing legal, reimbursement and stakeholder-risk that could pressure margins or create uncertainty around commercial terms. Litigation and policy disputes can weigh on near-term sentiment. Sagebrush sues Amgen over 340B program row
• Negative Sentiment: Sanford C. Bernstein downgraded Amgen to a Hold / lowered its rating, which can trigger selling or reduced conviction among institutional investors and contribute to downward pressure. Bernstein downgrades Amgen (AMGN) to a Hold

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 3,139 shares of the stock in a transaction that occurred on Thursday, November 20th. The shares were sold at an average price of $337.26, for a total transaction of $1,058,659.14. Following the completion of the sale, the senior vice president directly owned 7,225 shares of the company’s stock, valued at $2,436,703.50. This trade represents a 30.29% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Murdo Gordon sold 6,879 shares of Amgen stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $336.83, for a total transaction of $2,317,053.57. Following the sale, the executive vice president owned 41,923 shares in the company, valued at approximately $14,120,924.09. The trade was a 14.10% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 10,908 shares of company stock worth $3,674,966. 0.76% of the stock is owned by corporate insiders.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.